We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Restricts BioMed IRB After Two Failed Inspections
FDA Restricts BioMed IRB After Two Failed Inspections
April 25, 2012
The FDA has halted approval of new trials and enrollment in ongoing studies reviewed by BioMed IRB after two negative assessments of the board’s work.